Rapidness of leukocyte engraftment in patients receiving peripheral blood stem cell transplantation (PBSCT) is clinically important, because the risk of fatal opportunistic infections increases with time to engraftment. Adhesion receptor molecules on hematopoietic stem cells (HSC) have been shown to modulate homing and engraftment of HSC. Therefore we correlated expression levels of α4 (CD49d) and α6 (CD49f) integrins in the CD34+ HSC compartment with time to engraftment.
Introduction
The very late antigen (VLA) molecules, first described in by Takada et al. 1 are heterodimeric molecules that are involved in embryogenesis, leukocyte adhesion, cell migration, inflammation and extracellular matrix interaction. α4β1/VLA4
(CD49d/CD29), counter-receptor for VCAM-1 and fibronectin, as well as α6β1/VLA6/laminin receptor (CD49f/CD29) are ubiquitously expressed in human and mouse hematopoietic stem and progenitor cells and both play a role in homing and engraftment of hematopoietic stem cells. [2] [3] [4] [5] [6] Recent evidence from murine transplantation models suggests that α4-chain deletion 5 or treatment with functionblocking antibodies to α4 or α6 integrin 4 may impair hematopoietic engraftment. In contrast it is reported that blockage with α6 integrin antibodies improves engraftment efficiency in human hematopoietic stem cells (HSC). 2 These data suggest, that surface levels and function of VLA4 and VLA6 on stem cells may modulate stem cell engraftment.
However, all these experiments refer to stem cell engraftment in isogenic or immunodeficient (HSC) mouse transplantation models. Until now there is lack of evidence about the role of HSC α4 and α6 integrin expression levels for human peripheral blood stem cell transplantations (PBSCT) so far.
Here we demonstrate that low levels of α4 integrin expression on HSC are associated with a longer engraftment period in patients receiving autologous PBSCT.
We found no correlation of α6 integrin expression on HSC with engraftment velocity in this patient collective. 
Flow Cytometric Analysis
After washing with PBS+HA buffer, cells were resuspended to a concentration of 10 6 /ml. The following antibodies were used: CD34 Pe-Cy7, CD38 PerCP-Cy5. 
Results and Discussion
We determined the surface expression levels of α4 integrin and α6 integrin on CD34+ stem cells in leukapheresis products of 103 patients (Table 1) In addition, we performed a logistic regression analysis and found that the α4 integrin expression level had a significant inverse association with the probability of slow engraftment (p=0.003). In contrast such a positive association between the dosage of CD34+ cells and the probability of slow engraftment could not be shown (p=0.449). In detail, this analysis revealed, that the odds for slow engraftment decrease by 3.7%
with an increase of alpha4 expression by 1 unit. The association of α4 integrin levels and rapidity of engraftment was also significant in two uniform cohorts of patients analyzed separately (lymphoma and myeloma) (suppl. Figure 1 ).
For α6 integrin surface expression we found no correlation with time to engraftment, neither in CD34+CD38-HSC nor in the total CD34+ stem and progenitor cell compartment ( Figure 1A ).
VLA molecules show high expression levels in bone marrow stem cells and treatment with G-CSF leads to down-regulation of these integrins on HSC so that they can be released into the periphery. 2 Nevertheless α4 levels on mobilized HSC differed significantly between patients with slow and normal engraftment in spite of down-regulation and consecutively low receptor expression in comparison to untreated whole marrow HSC (data not shown). However, the differences of the Figure 1C ). Thus determination of α4 integrin levels on HSC in comparison to T-cells should be the preferred analysis method as depicted in Figure 1D .
In line with previous data about the importance of VLA4 for stem cell homing and engraftment derived from conditional deleted knock out mice systems 5, 6 or antibody blocking experiments 8 we show that the level of α4 integrin expression, but not α6 expression on CD34+ cells correlated significantly with PBSC engraftment, independent of the total number of CD34+ cells and/or history of radiation therapy.
Our finding may have clinical impact, because anticipation of PBSC engraftment capacity from α4 integrin determination on HSC could be a valuable information in the clinic. In line with this, drugs that are known to down-regulate these adhesion receptors such as histone deacetylase inhibitors 9 could influence engraftment and should therefore be handled with care in patients receiving PBSCT. On the other 8 / 1 3 hand drug induced up-regulation of adhesion molecules on transplanted HSC could be a promising strategy to facilitate engraftment in patients receiving PBSCT.
In summary flow cytometric measurement of α4 integrin levels on HSC is easy to perform and may therefore provide a new diagnostic tool for assessment of homing and engraftment capacity of stem cells from leukapharesis products in patients receiving PBSCT. Table 1 Characteristics of patients with slow and regular engraftment after autologous
PBSCT.
The patients were classified according to the leukocyte regeneration time as slow (>19 days) and regular (<19 days) engraftment. There was no significant difference in CD34+ cell numbers or age, while the amount of patients that received radiotherapy prior to PBSCT was slightly lower in slow engraftment group. For personal use only. on August 16, 2017. by guest www.bloodjournal.org From
